Abstract 1413P
Background
The phase 2 LUMINOSITY trial (NCT03539536) of Teliso-V monotherapy has shown acceptable safety & promising efficacy in previously treated patients (pts) with c-Met OE, EGFR WT, NSq NSCLC. Interim PRO data are reported.
Methods
Pts received Teliso-V (1.9 mg/kg) Q2W. PROs were assessed using the European Organisation for Research and Treatment of Cancer quality of life (QOL) questionnaires in lung cancer (LC13) & palliative cancer care (C15-PAL). Time to deterioration (TTD) beyond meaningful change threshold (MCT; ≥10 points from baseline) & mean change from baseline (mCFB) were analyzed.
Results
59 pts were evaluated. Median no. of prior therapies was 1 (range 1–3); median follow-up was 81 d. The table shows median TTD. For cough, pain in chest, pain in other parts, & QOL domains where median TTD was not reached, mCFB analyses revealed initial trends toward improvement. Cough, pain in chest, & overall QOL improved beyond MCT in wk 41, 49, & 41, respectively; pain in other parts trended toward deterioration. mCFB analyses revealed trends toward improvement for the LC13 symptom of hemoptysis, and for alopecia, sore mouth. Peripheral neuropathy deteriorated beyond MCT; dysphagia showed no consistent time trend. For C15-PAL, mCFB trend improved for nausea and vomiting, dyspnea (improved beyond MCT in wk 41), pain, fatigue, emotional function, and insomnia over a sustained duration for ≥29 wk, then deteriorated. Appetite loss worsened initially but improved in wk 41. Constipation improved initially then trended toward deterioration in wk 41 & 45.
Conclusions
This interim analysis suggests extended TTD and trends toward improvement from baseline in key lung cancer symptoms, physical functioning, & QOL; and deterioration in peripheral neuropathy. Impact of Teliso-V monotherapy on PROs will also be assessed at LUMINOSITY trial conclusion and in the phase 3, TeliMET NSCLC-01 trial (NCT04928846). Table: 1413P
Time to deterioration in symptoms, functional domains, and QOL
Instrument | Domains | Event/N | Median TTD, wk (95% CI) |
LC13 | Cough | 7/59 | NR |
Dyspnea | 22/59 | 33 (12, NE) | |
Pain in chest | 9/59 | NR | |
Pain in arm/shoulder | 22/59 | 20 (12, 34) | |
Pain in other parts | 17/59 | NR | |
C15-PAL | QOL | 18/59 | NR |
Physical function | 20/59 | 43 (8, NE) |
NE, not estimable; NR, Kaplan-Meier curve did not reach 50%.
Clinical trial identification
NCT03539536.
Editorial acknowledgement
Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
S. Lu: Financial Interests, Institutional, Research Grant: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, Hansoh; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Hansoh; Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co, Roche; Financial Interests, Institutional, Advisory Board: AstraZeneca, Roche, Mirati Therapeutics. J. Bar: Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Institutional, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. N. Girard: Financial Interests, Institutional, Research Grant: AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sivan, Trizell; Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Myers Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, Sivan; Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Leadership Role: International Thymic Malignancy Interest Group; Financial Interests, Personal, Other: AstraZeneca. Q. Xu, R. Sen, C. Ratajczak, S. Ng, S. Xia: Financial Interests, Institutional, Full or part-time Employment: AbbVie. D.R. Camidge: Financial Interests, Institutional, Speaker, Consultant, Advisor: AbbVie, Amgen, Astellas BioPharma, AnHeart Therapeutics, Apollomics, AstraZeneca, BeiGene, Bio-Thera, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, EMD Serono, GSK, Helsinn Therapeutics, Hengrui Pharmaceutical, Janssen, Kestrel Labs, Lilly, Mersana, Nuvalent, Inc., OnKure, Pfizer, Puma Biotechnology, Qilu Pharmaceutical, Ribon Therapeutics, Roche, Sanofi, Seattle Genetics, Takeda, Turning Point Therapeutics; Financial Interests, Institutional, Research Funding: Inivata (Inst).
Resources from the same session
1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Presenter: Jin-Ji Yang
Session: Poster session 20
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1382P - Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Presenter: Christian Rolfo
Session: Poster session 20
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Presenter: Guilherme Harada
Session: Poster session 20
1385P - Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Presenter: Monica Chen
Session: Poster session 20
1386P - Validation of MET amplification using next-generation sequencing in lung adenocarcinoma
Presenter: Marta Salido
Session: Poster session 20
1387P - Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study
Presenter: haifeng sun
Session: Poster session 20
1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Presenter: Shirish Gadgeel
Session: Poster session 20